Silence Therapeutics (SLN)

• Market cap: $253M
• 1 day: -5.42%
• 5 days: -8.50%
• 1 month: -20.19%
• 3 months: 1.20%
• 6 months: 7.89%
• Year to date: -29.62%
• 1 year: -72.33%
• 5 years: -74.05%
• 10 years: -74.05%
• Sector: Healthcare
• Industry: Biotechnology

About: Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

Employees: 116

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

1,786% more call options, than puts

Call options by funds: $132K | Put options by funds: $7K

78% more capital invested

Capital invested by funds: $60.7M [Q1] → $108M (+$47.1M) [Q2]

50.38% more ownership

Funds ownership: 15.47% [Q1] → 65.85% (+50.38%) [Q2]

10% less funds holding

Funds holding: 60 [Q1] → 54 (-6) [Q2]

37% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 19

38% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 13

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $35 592% upside
• Avg. target: $55 987% upside
• High target: $75 1,382% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Chardan Capital Keay Nakae	592% upside $35	Buy Maintained	8 Aug 2025
HC Wainwright & Co. Patrick Trucchio	1,382% upside $75	Buy Reiterated	13 Jun 2025